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Systemic inflammation, as evidenced by elevated inflammatory cytokines, is a recognised feature of advanced renal failure and predicts worse survival. Dialysate IL-6 concentrations are associated with variability in peritoneal small solute transport rate (PSTR) which has also been linked to patient survival. The purpose of this analysis is to determine the link between systemic and intra-peritoneal inflammation and establish their relation to membrane function and patient survival.
The Global Fluid Study is a multi-national, multicentre, prospective, combined incident and prevalent (n=959 patients) cohort study with up to 8 years follow-up. Data collection included detailed demography, comorbidity, modality, prescription and membrane function. Dialysate and plasma cytokines were measured by electrochemiluminescence. 
426 survival endpoints occurred in 559 incident and 358 prevalent patients from 10 centres in Korea, Canada and the UK. On entry to the study there was dissociation between systemic and intra-peritoneal cytokine networks with evidence of local production within the peritoneum. After adjustment for multiple covariates, systemic inflammation was associated with age and comorbidity and was an independent predictor of patient survival in both incident and prevalent cohorts. In contrast, intra-peritoneal inflammation was the most important determinant of PSTR but did not affect survival. In prevalent patients the relationship between local inflammation and membrane function persisted but did not account for an increased mortality associated with faster PSTR.






Individual differences in peritoneal membrane function have been shown to influence clinical outcomes in peritoneal dialysis (PD) patients. In particular a high peritoneal solute transport rate (PSTR) has been linked to worse survival.1 This association has been considered to be due to one of two main mechanisms – less efficient ultrafiltration and excess fluid reabsorption as a consequence of early loss of the glucose gradient during the dialysis dwell2 or because high PSTR is a manifestation of the systemic inflammation commonly seen in advanced kidney failure.3,4 The picture is further complicated by changes in PSTR due to acquired membrane injury with time on PD,5 where in addition to reducing ultrafiltration by the above mechanisms it can be associated with a reduction in membrane efficiency (reduced osmotic conductance).6,7 






Description of incident and prevalent cohorts 
The clinical characteristics of the 959 patients included in the analyses are shown in Table 1. Comparing the incident and prevalent groups the latter used more icodextrin and APD, greater total dialysate volumes and had lower urine volume.  Although the use of APD was relatively low, this was much more likely to be prescribed in patients with faster PSTR (0.78 v 0.7, P=0.0005). For the PET 57.3% of incident and 59.4% prevalent  patients used 2.5% glucose bags .
For most patient characteristics and prescription practices there were highly significant centre effects (for intra-cluster correlations see table 2 in supplementary material) and for this reason all linear regression models used multi-level methods. 
Demonstration that local peritoneal and systemic inflammation is uncoupled
To establish that dialysate IL-6 is representative of a localised inflammatory process is it necessary to demonstrate both local production and an association with other pro-inflammatory cytokines that is independent of plasma. Taking molecular size into account, 87% of subjects had dialysate IL-6 concentrations higher than predicted by diffusion across the peritoneal membrane (Figure 1). Values for IL-1, TNF- and IFN- were 33.3%, 6.9% and 45.7% respectively. Within the peritoneal and circulatory compartments there were moderate to strong correlations between the measured cytokines reflecting localised activation of pro-inflammatory networks (Table 2). In contrast, correlations between dialysate and plasma were either absent or weaker than those seen within blood or dialysate. 
Local not systemic inflammation is the main determinant of PSTR
Results of the multivariable, multilevel, linear regression models showing the associations with PSTR are displayed in table 3. Dialysate IL-6 concentration was the most significant association in both patient cohorts, a pattern observed in all of the participating centres, (see Figure 2). This was independent of patient factors (gender, race, BMI, BP, urine volume, diabetic status) and dialysis prescription, all of which had significant associations. For incident patients, the timing of the initial membrane function assessment had an effect that was not linear: tests done early, i.e. from baseline the PSTR rose for 2 months, increasing by 0.08, then fell to a total gain of 0.06 by 3 months. In prevalent patients, higher PSTR was associated in a linear fashion with longer time on treatment. Cytokine concentrations produced a better model than appearance rates (Δ-2 LL = 36).
Factors associated with local and systemic inflammation
Before proceeding to survival analyses it was necessary to determine the clinical associations with local (Table 4) and systemic (Table 5) inflammation as defined by the dialysate and plasma IL-6 concentrations respectively.
Local membrane inflammation was associated with older age, lower systolic blood pressure, use of icodextrin, local TNF- and systemic IL-6 concentrations in incident and prevalent patients. Factors associated with systemic inflammation were similar where a reciprocal effect might be expected (e.g. the plasma and dialysate cytokines) but also included a relationship with comorbidity; in prevalent patients this was with the overall comorbid burden whereas in prevalent patients it was especially evident with diabetics (although the IL-6 levels were still different between the grades of comorbidity, one-way between subjects ANOVA, p=0.006). 
Sensitivity analyses excluding one centre with marginally less good data quality increased the significance of the association between plasma IL-6 and age (p=0.02) in prevalent patients.
Systemic not local inflammation predicts patient survival





This analysis of the Global Fluid Study clearly shows that systemic and local peritoneal inflammatory cytokine networks are uncoupled and that they have different consequences for patient survival. Local, subclinical peritoneal inflammation is demonstrated to be the strongest known factor associated with between patient variability in PSTR, independent of centre effects, and the lack of an association with survival refutes the prior hypothesis that fast PSTR increases mortality through its association with systemic inflammation. If anything, evidence points to intra-peritoneal inflammation being a contributor to systemic inflammation without influencing its association with mortality.
Although the association between local inflammation and PSTR has been found in prior studies 8,9,16 none of these has had either the power or the degree of detailed clinical data to show its relative importance compared to previously demonstrated, much weaker, clinical associations. As with CANUSA,17 ANZDATA18 and the Stoke PD Study4,19, diabetics and males were found to have higher PSTR, whereas the association with increasing age, overall comorbidity and inverse relationship to BMI were not seen. This is also the first study to identify important centre effects and include adjustment for these in the analytic approach. These centre effects will reflect differences such as case mix and race, practice patterns related to dialysis and EPO prescription which could largely be adjusted for, but also differences in PSTR that are likely to reflect local variations in exactly how the peritoneal equilibration test (PET) is performed or biochemically analysed, as well as unknown factors. Timing of the initial PET showed a complex relationship from which it is possible to infer that there is an early increase in PSTR within the first four weeks of treatment with a subsequent fall before a longer term increase in keeping with previous reports.19,20,21 Given the ANZDATA’s finding that race influenced PSTR 18 it is interesting that this was found to be higher in Korean patients, independent of IL-6 levels, suggesting that other genetic factors might be important.
It is difficult to disentangle the observed association between use of either icodextrin or higher glucose concentration solutions with higher dialysate IL-6 concentrations given that they also associate with PSTR and thus there may be some confounding by indication. However, icodextrin in combination with other solutions has been associated with increased solute transport, 22,23  as have other biocompatible solutions at the commencement of treatment with PD.24 One possible explanation is that more biocompatible dialysate improves local cell viability and thus facilitates the local production of  cytokines or vaso-active mediators.25,26 In light of the recently published balANZ study in which use of a biocompatible solution was associated with disappearance of the increase in solute transport with time on PD,24 it is interesting to note in this study that prevalent patients using these solutions had lower PSTR.
The associations between plasma IL-6, other systemic inflammatory cytokines and comorbidity were to be expected and are in keeping with the previously described relationship between IL-6 polymorphisms, comorbidity and survival in haemodialysis and PD patients.12,27 More surprising is the association between plasma and dialysate IL-6. This could reflect the fact that genetically high IL-6 producers more readily synthesise more of this cytokine in any of the body compartments.10 Alternatively, the high concentrations in dialysate, which in some of these patients was >1000 times that of plasma despite the diluting effects of two litres of instilled solution, reflects peritoneal membrane concentrations that could spill over into plasma.
The relationship between systemic inflammation and survival, independent of age and comorbidity was as anticipated, although previous studies have not reported independent effects of TNF-α and IL-6 as observed here in incident patients.28,29 There were other potentially important differences between the incident and prevalent cohorts, partly because prevalent patients are by definition a self-selected cohort. As would be expected, longer duration of PD was a risk factor for worse survival. Relative preservation of residual urine volume, in keeping with prior studies, is more important than for incident patients whereas it’s likely that the patients with the lowest plasma albumin concentrations will have already died explaining the lack of association with survival. It is interesting to note that in these prevalent patients increased solute transport was associated with reduced survival; this may be because the relative importance of membrane function would be expected to increase as residual function becomes more critical. Although the use of APD at the start of PD in the GFS cohort is relatively low, it was used preferentially in patients with high PSTR and with double the frequency in prevalent compared to incident patients. In contrast to most published cohorts, icodextrin use was high. 
This study has a number of limitations. Despite the depth and completeness of the clinical data collected and attempts to account for important observed centre effects, it must be acknowledged that there are likely to be practice patterns and local factors that remain poorly understood and/or unmeasured. Whilst the study used 10 centres from 3 countries a degree of selection bias might be present as the selected centres had better data quality. As with any observational study, direction of causality must always be questioned. The genetic associations between high producing IL-6 polymorphisms and membrane function, effectively Mendelian randomisation experiments, strongly suggest that activation of local cytokine networks are the cause rather than the consequence of increased PSTR, which is also biologically plausible. However there were a number of statistical associations demonstrated that do not have clear biological explanations. For example, a lower systolic blood pressure was associated with higher dialysate but not plasma IL-6 concentration. These require reproducing in separate cohorts and further investigation. Despite clear evidence of local production in some patients, average dialysate TNF-α levels were less than predicted by the 3 pore model, but the results were biologically plausible and compatible with previous studies. 30 Controversy exists as to whether dialysate biomarkers should be expressed as absolute concentrations or appearance rates. In our multivariable analysis, dialysate IL-6 concentrations produced better models than appearance rates suggesting biological effects are determined by concentration, mediated by changes over log orders. Correcting for appearance rates produced worse models, probably because the dialysate samples were all standardised to 4 hour dwells and a recent study has shown a linear increase in IL-6 concentrations with time. 31 






The Global Fluid Study is an international, multi-centre, prospective, observational cohort study designed to answer a series of research questions seeking to relate peritoneal membrane function to local and systemic biomarkers as predictors of predefined clinical endpoints (e.g. patient survival, membrane injury). In was open to any centre worldwide as advertised at international meetings. 10 centres from the UK, Korea and Canada were finally included (see table 1 in supplementary material) in this analysis. An additional 6 centres (comprising 247 patients) were excluded based on a pre-analysis assessment indicating poor data quality (more than 10 variables were missing more than 10% of data) and it was judged unlikely that this could be improved upon due to logistic issues. Recruiting incident (within first 90 days of PD) and prevalent patients, enrolment commenced in June 2002, and finished in December 2008 (with some centres stopping before then), with follow-up censored at centre-specific dates during December 2010. Any patient on peritoneal dialysis was eligible for inclusion provided they could give informed consent.  The sample size was the maximum logistically feasible, as determined by each centre. Dialysate sampling was from a 4 hour peritoneal equilibration test (PET), with some centres also collecting samples from an overnight dwell. Simultaneous clinical data were collected and stored in a purpose built Peritoneal Dialysis Access database (PDDB). Ethical approval was obtained from the Multi-Centre Research Ethics Committee for Wales covering the UK, whilst local country ethics were obtained for other contributing countries.

Prospective collection of routine clinical measurements
Routine demography was recorded and comorbidity documented using the validated Stoke Comorbidity Index that both categorises patients into low (score 0), intermediate (score 1-2), and high (score >2) risk groups, and enables analysis by individual comorbidities within the index. Patient level ethnicity was not available so this was recorded as non-Korean vs Korean based on centre. Routine blood, urine and dialysate tests were performed locally and, if necessary, converted into standardised SI units.
PD related measurements included residual renal function (mean of urea and creatinine clearances), dialysis regime and dose, and peritoneal membrane function using the peritoneal equilibration test (solute transport rate: dialysate to plasma creatinine ratio (PSTR) and net UF capacity at 4 hours with 2.27% or 3.86% glucose, corrected for flush volume, if included in the measurement). The glucose exposure rate was calculated as total grams of glucose within the daily dialysate, and the average daily glucose concentration was the total daily dialysate glucose/total daily dialysate volume (grams/litre). Biocompatible solutions were defined as any solution with low glucose degradation products.

Sample analysis
Dialysate and plasma samples were stored locally at -800C, then transferred frozen to a central laboratory in the UK. Plasma and 4 hour dialysate samples (excluding overnight samples) were assayed for IL-1β, TNF-α, IFN-γ and IL-6 by electrochemiluminescence immune assay, using the commercially available Pro-Inflammatory I 4-plex (Meso-Scale Discovery, Gaithersburg, Maryland, USA). Triplicate measurements were made, the mean of which was used. 
Statistical analysis
Demographic features were compared with independent sample t-tests, Mann-Whitney U tests or chi-squared tests, depending on whether the variable was normally distributed, skewed or categorical. Similarly for centre effects, one-way ANOVA or Kruskal-Wallis was used (table 1).
Pearson’s R was used for cytokine correlations with Sidak’s adjustment for multiple comparisons and a p value of 0.05 for statistical significance. The 3 pore model was used to predict 4 hour cytokine D/P ratios based on the predicted molecular radius. 32 For plasma values of 0 with detectable dialysate cytokine, a ratio greater than 1 was assumed; if both dialysate and plasma cytokine were undetectable, a ratio of 0 was assumed.
3 multilevel linear models for predictors of the continuous variables PSTR, and log10 transformations of dialysate and plasma IL-6 concentrations in 3 separate models were run to account for the observed centre effects by introducing a centre level residual as well as the usual person level residual. As an exploratory analysis, no adjustment of significance levels was made for multiple hypotheses tested. Random intercept models were fitted, (random slopes models were attempted but did not converge). The variable selection method was to include all cytokine measures and all the important clinical and available demographic variables. Dialysate IL-1β was dropped and only 1 measure of BP included due to multi-colinearity. Diabetes and comorbidity were included in separate models as existing literature suggests diabetic effects may be important independently of the comorbidity score, despite being highly correlated.33 The duration of PD was included as either a linear or linear plus quadratic term in the incident group, as suggested by existing literature.20 The Iterative Generalised Least Squares method was used for coefficient estimation and residuals were checked for normality. For clarity of interpretation, 23 patients with a previous episode of PD were excluded from the prevalent group multilevel modelling.
We included cytokine results in the PSTR model as either concentrations (as shown) or appearance rates, and selected the type that provided the best goodness of fit as measured by -2LL values. The selected variable type was then used in all other analyses.
Cox modelling, stratified by centre, was used for survival analysis, with robust standard errors. Hazard Ratios for cytokines quoted are for a log10 change in concentration. Proportional hazards were checked with log-log plots, scaled Schoenfeld residual plots and significance testing. Dialysate IL-1β was excluded due to high collinearity.
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Table 1: Study population characteristics
 	IncidentN = 575	Centre Effect (p value)	PrevalentN=384	Centre Effect (p value)	Difference between incident and prevalent (p value)
Age (years)	55.6 (15.3)	0.001	54.2 (15.2)	0.037	NS
Female Gender	38.4%	NS	46.4%	NS	0.05
Korean	37.2%		36.2%		NS
BMI (kg/height2)	25.2 (4.7)	<0.001	25.3 (4.7)	<0.001	NS
Total dialysate volume (litres)	7.96 (1.29)	<0.001	8.38 (1.87)	<0.001	<0.001
Blood pressure (mmHg)	136/80 (21/12)	<0.001	135/81 (20/12)	NS	NS
Duration of PD (days; median)	40 (28, 55)	<0.001	360 (169, 609)	<0.001	<0.001
4 hour PSTR	0.71 (0.12)	<0.001	0.71 (0.12)	<0.001	NS
UF capacity (mls)S Strong M Medium Bags Used	S  696.9 (18.4)M 229.3 (17.6)	<0.001<0.001	S 721.9 (22.5)M 248.6 (17.0)	0.03<0.001	<0.001<0.001
Albumin	35.0 (5.2)	<0.001	35.4 (4.8)	0.06	NS
Haemoglobin	11.0 (2.2)	<0.001	11.2 (1.8)	<0.001	NS





Figures are mean (SD) unless percentage given for categorical or median (IQR) for  skewed variable. NS = Not significant.


























Table 3: Predictors of PSTR 
	Incident	Prevalent
	Coefficient (95% CI)	p value	Coefficient(95% CI)	p value
Age(per decade)	0.001(-0.005, 0.008)	0.7	-0.004(-0.012, 0.004)	0.4
BMI	  -0.002 *(-0.005, -0.0001)	0.04	-0.0009(-0.004, 0.002)	0.5
APD usage	-0.02(-0.06, 0.02)	0.3	-0.008(-0.04, 0.03)	0.7
Systolic BP(per 10mmHg)	   0.005 *(0.0002, 0.009)	0.04	0.001(-0.004, 0.007)	0.6
Male Gender	 0.02 *(0.003, 0.04)	0.02	 0.02 *(0.002, 0.05)	0.04
Duration of PD 	 0.08 x month **(0.03, 0.13), -0.02 x month2 *(-0.04, -0.003)	<0.001	  0.01 x year **(0.004, 0.02)	0.003
Biocompatible Solution Usage	-0.005(-0.02, 0.02)	0.7	 -0.04 *(-0.07, (-0.004)	0.03
Icodextrin Usage	   0.06 **(0.03, 0.09)	<0.001	 0.04 *(0.01, 0.07)	0.01
Average glucose concentration(per gramme/litre)	   0.005 **(0.002, 0.007)	<0.001	0.005 ** (0.001, 0.008)	0.004
Dialysate IL-6 	  0.08 **(0.06, 0.11)	<0.001	0.09 **(0.07, 0.12)	<0.001
Dialysate TNF-α	0.04(-0.03, 0.10)	0.3	-0.03(-0.1, 0.06)	0.6
Dialysate IFN-γ	-0.009(-0.04, 0.02)	0.6	0.008(-0.03, 0.04)	0.6
Plasma IL-6	-0.02(-0.06, 0.01)	0.2	0.006(-0.04, 0.05)	0.8
Plasma TNF-α	0.02(-0.04, 0.09)	0.5	-0.05(-0.12, 0.02)	0.2
Plasma IFN-γ	-0.009(-0.04, 0.02)	0.6	-0.02(-0.06, 0.03)	0.4
Plasma IL-1β	0.02(-0.06, 0.11)	0.6	0.001(-0.09, 0.09)	0.98
Diabetic	  0.02 *(0.001, 0.05)	0.04	0.004(-0.03, 0.03)	0.8
Comorbidity	0.0005(-0.01, 0.01)	0.9	0.003(-0.01, 0.02)	0.7
Urine volume (per litre)	   0.03 **(0.01, 0.04)	<0.001	0.02 *(0.005, 0.04)	0.01
Korean	0.08 *(0.01, 0.15)	0.02	0.05(-0.005, 0.11)	0.07
* p 0.01 – 0.05, ** p <0.01. Data are presented so that coefficients represent the change in D/P Cr. 499 and 307 patients were in the final models for incident and prevalent patients respectively. Cytokine coefficients are per log10 changes in concentration.
Table 4: Predictors of log dialysate IL-6
	Incident	Prevalent
	Coefficient	p value	Coefficient	p value
Age (per decade)	   0.04 **(0.01, 0.06)	0.002	0.05 **(0.01, 0.08)	0.01
BMI	0.0009(-0.007, 0.009)	0.8	 0.008(-0.003, 0.02)	0.2
APD Usage	-0.06(-0.21, 0.10)	0.5	0.2(-0.004. 0.3)	0.06
Systolic BP (per 10mmHg)	 -0.02 *(-0.03, -0.002)	0.03	 -0.03 **(-0.05, -0.002)	0.03
Male Gender	0.04(-0.04, 0.11)	0.3	0.1(-0.0003, 0.2)	0.051
Duration of PD(per year)	0.1(-0.6, 0.8)	0.7	0.02(-0.02, 0.05)	0.4
Biocompatible solution usage	0.0007(-0.09, 0.09)	0.99	0.1(-0.04, 0.3)	0.1
Icodextrin Use	  0.3 **(0.2, 0.4)	<0.001	 0.2 **(0.07, 0.3)	0.003
Average Glucose Concentration (per gramme/litre)	  0.01 **(0.004, 0.02)	0.006	-0.004(-0.02, 0.01)	0.5
Dialysate TNF-α 	  0.8 **(0.6, 1.0)	<0.001	0.7 **(0.3, 1.0)	0.001
Dialysate IFN-γ	0.006(-0.1, 0.1)	0.9	0.02(-0.1, 0.2)	0.8
Plasma IL-6 	  0.3 **(0.2, 0.4)	<0.001	0.3 **(0.1, 0.5)	0.001
Plasma TNF-α 	-0.2(-0.4, 0.06)	0.1	0.2(-0.1, 0.5)	0.2
Plasma IFN-γ	0.06(-0.06, 0.19)	0.3	-0.1(-0.3, 0.03)	0.1
Plasma IL-1β	-0.1(-0.3, 0.3)	0.9	-0.05(-0.5, 0.4)	0.8
Diabetic	0.01(-0.08, 0.10)	0.8	0.05(-0.08, 0.2)	0.4
Comorbidity	0.02(-0.03, 0.06)	0.5	-0.004(-0.06, 0.05)	0.9
Urine volume (per litre)	0.03(-0.02, 0.08)	0.2	-0.1 *(-0.2, -0.02)	0.01
Korean	-0.02(-0.2, 0.2)	0.8	-0.2(-0.5, 0.1)	0.3





Table 5: Predictors of log plasma IL-6
	Incident	Prevalent
	Coefficient	p value	Coefficient	p value
Age(per decade)	  0.02 **(0.007, 0.04)	0.004	0.01(-0.009, 0.03)	0.3
BMI	0.0001(-0.005, 0.005)	0.96	0.004(-0.002, 0.01)	0.2
APD Usage	0.04(-0.06, 0.14)	0.4	0.003(-0.08, 0.09)	0.9
Systolic BP (per 10mmHg)	0.003(-0.007, 0.014)	0.5	-0.009(-0.02, 0.004)	0.2
Male Gender	0.05(-0.001, 0.09)	0.06	0.02(-0.03, 0.07)	0.5
Duration of PD(per year)	-0.2(-0.6, 0.2)	0.4	0.02 *(0.0008, 0.03)	0.04
Biocompatible solution usage	0.003(-0.05, 0.06)	0.9	-0.02(-0.10, 0.06)	0.6
Icodextrin usage	0.04(-0.02, 0.11)	0.3	-0.02(-0.09, 0.05)	0.6
Average Glucose Concentration(per gramme/litre)	0.003(-0.004, 0.009)	0.4	-0.002(-0.01, 0.005)	0.5
Dialysate IL-6 	  0.13 **(0.07, 0.18)	<0.001	0.09 **(0.03, 0.15)	0.002
Dialysate IFN-γ	0.07 (-0.003, 0.15)	0.06	0.04(-0.04, 0.1)	0.3
Dialysate TNF-α	-0.2 *(-0.3, -0.005)	0.04	-0.1(-0.4, 0.06)	0.2
Plasma TNF-α	  0.4 **(0.2, 0.5)	<0.001	0.4 **(0.2, 0.5)	<0.001
Plasma IFN-γ	0.05(-0.03, 0.13)	0.2	0.2 **(0.07, 0.3)	0.001
Plasma IL-1β	0.2 *(0.001, 0.4)	0.049	0.3 *(0.07, 0.5)	0.01
Diabetic	-0.05(-0.1, 0.007)	0.09	0.07 *(0.002, 0.15)	0.045
Comorbidity	  0.05 **(0.02, 0.08)	0.001	0.02 (-0.01, 0.05)	0.2
Urine Volume(per litre)	-0.02(-0.05, 0.01)	0.3	-0.009(-0.05, 0.03)	0.7
Korean	0.03(-0.05, 0.11)	0.4	-0.04(-0.1, 0.1)	0.4




Table 6: Predictors of survival
	Incident	Prevalent
	Hazard Ratio(95% CI)	p value	Hazard Ratio(95% CI)	p value
Dialysate TNF-α	0.99(0.34, 2.89)	0.98	0.86(0.22, 3.43)	0.8
Dialysate IL-6	 0.93(0.66, 1.31)	0.7	0.96(0.65, 1.44)	0.9
Dialysate IFN-γ	1.18(0.69, 2.00)	0.5	1.20(0.65, 2.19)	0.6
Plasma IL-1β	0.56(0.15, 2.15)	0.4	0.52(0.16, 1.74)	0.3
Plasma TNF-α	3.39 *(1.26-9.16)	0.02	2.03(0.52, 7.93)	0.3
Plasma IL-6	2.15 **(1.22, 3.78)	0.008	2.68 **(1.28, 5.58)	0.009
Plasma IFN-γ	0.89(0.49, 1.60)	0.7	1.16(0.62, 2.16)	0.6
Age                    (per year)	1.06 **(1.05, 1.08)	<0.001	1.06 **(1.04, 1.07)	<0.001
Male Gender	0.94(0.69, 1.29)	0.7	1.28(0.92, 1.78)	0.1
Comorbidity   (per disease)	1.68 **(1.44, 1.96)	<0.001	1.37 **(1.18, 1.58)	<0.001
Urine volume  (per litre)	0.95(0.76, 1.19)	0.7	0.65 **(0.48, 0.87)	0.004
Duration of PD(per month)	1.17(0.05, 29.16)	0.9	1.14 **(1.04, 1.24)	0.005
Albumin           (per 1 g/dl)	0.94 **(0.91, 0.97)	<0.001	0.99(0.95, 1.03)	0.6
PSTR                  (per 0.1 increase in D/P Cr)	1.10(0.98, 1.23)	0.1	1.18 *(1.003, 1.41)	0.049
BMI	1.01(0.97, 1.05)	0.6	1.01(0.98, 1.04)	0.6





Figure 1: Graph of dialysate to plasma concentration ratio (y axis) for IL-6 concentrations. The line represents the ratio predicted by the 3 pore model (0.145) so all points above this line are predicted to represent local production. 



























Table 1: List of centres
Country	Centre	Included	Patient Numbers




	Manchester Royal Infirmary, Manchester	Yes	116
	University Hospital of Wales, Cardiff	No	178
	Queen Elizabeth Hospital, Birmingham	No	9
Canada	Dr. Georges L.Dumont Hospital, Moncton 	Yes	41
	Edmonton General Hospital, Edmonton	Yes	70
Korea	Yeungnam University Hospital, Daegu	Yes	55
	Soon Chun Hyang University, Seoul	Yes	53 included(30 excluded due to missing batch of samples)
	Kyungpook National University Hospital, Daegu	Yes	245
Hong Kong	Princess Margaret Hospital, Kowloon	No	4
Israel	Carmel Hospital, Haifa	No	18
	Assaf Harofeh Hospital, Zrifin	No	18
Belgium	University Hopsital of Ghent, Ghent	No	20

Table 2: Intra-cluster correlations for PSTR, dialysate and plasma IL-6 
Variable	Incident	Prevalent
PSTR	0.17(0, 0.34)	0.17(0, 0.35)
Dialysate IL-6	0.18(0, 0.36)	0.15(0, 0.32)
Plasma IL-6	0.08(0, 0.17)	0.005(0, 0.037)
Data presented = ICC (95% CI)
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